	US 11,896,559 B2
	Opthalmic compositions comprising F6H8
Bernhard Günther, Dossenheim (DE); Frank Löscher, Schriesheim (DE); Hartmut Voss, Schriesheim (DE); Sonja Krösser, Heidelberg (DE); Kirsten Eickhoff, Heidelberg (DE); Daniela Willen, Oberzent (DE); Markus Beier, Weinheim (DE); and Thomas Schlüter, Heidelberg (DE)
Assigned to NOVALIQ GMBH, Heidelberg (DE)
Appl. No. 16/753,701
Filed by NOVALIQ GMBH, Heidelberg (DE)
PCT Filed Oct. 3, 2018, PCT No. PCT/EP2018/076908 § 371(c)(1), (2) Date Apr. 3, 2020, PCT Pub. No. WO2019/068763, PCT Pub. Date Apr. 11, 2019.
Claims priority of provisional application 62/568,138, filed on Oct. 4, 2017.
Prior Publication US 2020/0268682 A1, Aug. 27, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/02 (2006.01); A61P 27/04 (2006.01); A61K 9/00 (2006.01)

CPC A61K 31/02 (2013.01) [A61K 9/0048 (2013.01); A61P 27/04 (2018.01)]

20 Claims

1. A method of increasing tear film thickness and/or increasing the lipid layer thickness, wherein the method comprises the steps of: (a) administering to the eye of a patient in need thereof an amount of an ophthalmic composition consisting of a mixture of F(CF₂)₆(CH₂)₈H and 2-perfluorohexyloctane, optionally wherein the amount is effective to enrich an ophthalmic tissue in F(CF₂)₆(CH₂)₈H, and optionally (b) delayed release of F(CF₂)₆(CH₂)₈H from the enriched ophthalmic tissue;

wherein the ophthalmic composition is administered to the surface of the cornea and/or the conjunctiva in the form of liquid eye drops; and

wherein the patient suffers from keratoconjunctivitis sicca (dry eye disease).